Evidence map›Paper›PMID 41505404›Full record

ArticlePloS one2026

Multi-objective QSAR prediction of ERα antagonists via SHAP-based interpretation.

Jinhui Cao, Yanli Liu

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jinhui CaoSchool of Science, Wuhan University of Science and Technology, Wuhan, China.
Yanli LiuSchool of Science, Wuhan University of Science and Technology, Wuhan, China.ORCID https://orcid.org/0000-0001-6734-2601

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To achieve a comprehensive evaluation of candidate drugs in terms of both biological activity and ADMET properties, this study proposes a two-stage predictive framework based on Quantitative Structure-Activity Relationship (QSAR) modeling integrated with machine learning techniques, elucidating the quantitative relationships between molecular structure and pharmacological properties. A novel Dual-Filter Feature Selection (DFFS) method integrates statistical analysis and feature importance scores derived from machine learning models. The averaged rankings are used to obtain a robust set of molecular descriptors. In the first stage, 20 key two-dimensional molecular descriptors were selected via DFFS from ERα antagonists. RF, XGBoost, LightGBM, and gcForest-were employed for activity prediction. Experimental results indicated LightGBM achieved the best performance, with MRE of 0.0775. The comparative experiment demonstrates that under the same LightGBM regression framework, DFFS outperformed its individual components-Mutual Information and XGBoost-as well as the high-dimensional features generated by ChemBERTa. In the second stage, based on 40 descriptors selected by DFFS, a stacking model was constructed to perform multitask prediction of ADMET properties, ensuring that high-activity candidate compounds also exhibit favorable profiles in absorption, distribution, metabolism, excretion, and toxicity. The AUC scores for all five ADMET models exceeded 0.95. To elucidate the molecular mechanisms and interpret the model decisions, we applied Phi coefficient analysis to assess inter-property correlations and SHAP analysis to identify key molecular features governing compound activity. Furthermore, molecular docking was performed to evaluate the binding affinity of highly active compounds towards the target protein, thereby providing quantitative validation of the predicted biological activities.

Indexed as

Estrogen Receptor alphaEstrogen Receptor AntagonistsQuantitative Structure-Activity RelationshipBoosting Machine Learning AlgorithmsHumansMachine LearningPrediction AlgorithmsEstrogen Receptor alphaEstrogen Receptor Antagonists

Identifiers

PMID41505404
PMCPMC12782375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.